---
title: "Moderna CEO on next steps after intismeran Phase 3 success in melanoma"
id: "stat-news-1-stat-moderna-ceo-on-what-s-next-after-success-in-cancer-vaccine"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-moderna-ceo-on-what-s-next-after-success-in-cancer-vaccine"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/26/moderna-ceo-stephane-bancel-interview-cancer-vaccine-intismeran/?utm_campaign=rss"
published_at: "2026-10-26T08:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Moderna CEO on next steps after intismeran Phase 3 success in melanoma
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-moderna-ceo-on-what-s-next-after-success-in-cancer-vaccine
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/26/moderna-ceo-stephane-bancel-interview-cancer-vaccine-intismeran/?utm_campaign=rss)
- **Published At:** 2026-10-26T08:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Moderna and Merck partnered on a decade-long program that culminated in a Phase 3 trial showing benefit of the personalized mRNA cancer vaccine **intismeran** in **melanoma**. The source reported that investigators presented the data at the European Society for Medical Oncology meeting. - CEO Stéphane Bancel told STAT that the company intends to move quickly and “go as fast as we can” in seeking **FDA** approval for intismeran; the company plans regulatory filings, according to the interview. - The study was described in the source as the first Phase 3 study to demonstrate that a customized mRNA-based therapy could improve outcomes for patients with melanoma; the article noted a decade of research underpinning the program. - The partnership with **Merck** was explicitly cited in the source as boosting Moderna’s research efforts and helping bring the program to this point. - Bancel characterized the result as vindication after many prior attempts in cancer vaccines and said the clinical outcome felt “really special” given long-term work by many contributors. - The interview took place at the European Society for Medical Oncology annual meeting in Madrid; the conversation was described as wide-ranging but was condensed and edited for clarity. - The STAT story is a subscriber-exclusive piece; the published excerpt included quotes from Bancel, program history, and plans to pursue regulatory approval, while the remainder of the interview and full article require STAT+ access.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/26/moderna-ceo-stephane-bancel-interview-cancer-vaccine-intismeran/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/26/moderna-ceo-stephane-bancel-interview-cancer-vaccine-intismeran/?utm_campaign=rss) [Clinical trials](https://www.statnews.com/topic/clinical-trials/) [Cancer](https://www.statnews.com/topic/cancer/) [ethics](https://www.statnews.com/topic/ethics/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Moderna CEO on what’s next after success in cancer vaccine ## Stéphane Bancel said the company intends to ‘go as fast as we can’ in seeking FDA approval for intismeran * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/26/moderna-ceo-stephane-bancel-interview-cancer-vaccine-intismeran/?utm_campaign=rss) ![Moderna CEO Stephane Bancel looks up before testifying](https://www.statnews.com/wp-content/uploads/2023/03/GettyImages-1475304113-645x645.jpg) Moderna CEO Stéphane Bancel.Chip Somodevilla/Getty Images ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Oct. 26, 2026 Senior Writer, Biotech ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. MADRID — Moderna CEO Stéphane Bancel had every reason to be smiling and happy on a brilliantly sunny, Saturday afternoon here in Spain’s capital. In a couple of hours, a decade of the company’s research — boosted by a [partnership with Merck](https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/) — was going to culminate in the presentation of the first Phase 3 study to successfully demonstrate that a customized mRNA-based therapy called [intismeran could improve outcomes](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) for patients with melanoma. “It’s an amazing feeling,” he told STAT from the sidelines of the European Society for Medical Oncology annual meeting. “We’ve been working on intismeran for 10 years. Most people in the field thought this was never going to work, and many people had tried cancer vaccines before. But we were convinced, so it has been really special to be able to see all this work by so many people coming together to help patients.” Advertisement In a wide-ranging interview, Bancel spoke to STAT about [what’s next for intismeran](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/), and how the drug’s success impacts the company’s R&D and business strategies. The conversation has been condensed and edited for clarity. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Moderna](https://www.statnews.com/topic/moderna/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_1846705681_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Patient dies in Bristol Myers Squibb autoimmune CAR-T trial](https://www.statnews.com/2026/10/23/bristol-myers-squibb-car-t-therapy-autoimmune-trial-death/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/IMG_5891-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After a cancer vaccine’s first success, the race is on to expand the impact](https://www.statnews.com/2026/10/25/mrna-cancer-vaccine-merck-moderna-esmo-intismeran-next-applications/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AP24016081587973-80x80.jpg) [Christina Applegate puts a face on one of the most consequential challenges in neurology](https://www.statnews.com/2026/10/24/christina-applegate-multiple-sclerosis-why-ms-misdiagnosis-happens/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/06/GettyImages-2237096018-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [At ESMO, AstraZeneca’s cancer pursuits get a showcase](https://www.statnews.com/2026/10/25/esmo-astrazeneca-adcs-lung-gastric-cancer/) 5. ![](https://www.statnews.com/wp-content/uploads/2020/07/49666506826_3c5995bd7c_h-e1595620109289-80x80.jpg) [A first, small study suggests Omicron is a larger threat to Covid-19 immunity than other variants](https://www.statnews.com/2021/12/07/a-first-small-study-suggests-omicron-is-a-larger-threat-to-covid-19-immunity-than-other-variants/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_1846705681_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Patient dies in Bristol Myers Squibb autoimmune CAR-T trial](https://www.statnews.com/2026/10/23/bristol-myers-squibb-car-t-therapy-autoimmune-trial-death/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/05/AdobeStock_525738206_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_499879090-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer](https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/07/GLP1-48-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 24, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The ESMO presentation everyone’s been waiting for ](https://www.statnews.com/2026/10/24/the-esmo-2026-merck-moderna-presentation-amgen-imdelltra-news/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early ](https://www.statnews.com/2026/10/23/moderna-merck-melanoma-cancer-vaccine-data-arrived-early-esmo/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) and [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Patient dies in Bristol Myers Squibb autoimmune CAR-T trial ](https://www.statnews.com/2026/10/23/bristol-myers-squibb-car-t-therapy-autoimmune-trial-death/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials ](https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout October 23, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Tango builds on Revolution Medicines’ pancreatic cancer success ](https://www.statnews.com/2026/10/23/tango-pancreatic-cancer-star-moderna-readout-newsletter/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) and [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: How the No Surprises Act’s nonprofit arbitrators are operating like 'mini gods' and getting rich doing it ](https://www.statnews.com/2026/10/19/no-surprises-act-billing-arbitration-profits-stat-investigation/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugmaking? ](https://www.statnews.com/2026/10/19/can-isomorphic-labs-revolutionize-drugmaking/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) 3. ### [ I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying ](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) By Tyler Shultz 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Mark Cuban wants to crack open the market for rare disease treatments ](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) 5. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction ](https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-la
## Related Clinical Research

- [AstraZeneca’s oncology data took center stage at ESMO 2026](https://medichelpline.com/clinical-feed/stat-news-0-stat-at-esmo-astrazeneca-s-cancer-pursuits-get-a-showcase.md)
- [Moderna/Merck mRNA vaccine intismeran cuts melanoma recurrence risk by 42% with Keytruda](https://medichelpline.com/clinical-feed/stat-news-0-stat-after-a-cancer-vaccine-s-first-success-the-race-is-on-to-expand-the-impact.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Link Between Daily Sugary Drink Consumption and Increased Stomach Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-1-daily-sugary-drink-consumption-linked-to-more-than-double-stomach-cancer-risk.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.